ArticleClinical and translational medicine2022

Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.

Fangming Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.